IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v12y2021i1d10.1038_s41467-021-23883-6.html
   My bibliography  Save this article

Molecular benchmarks of a SARS-CoV-2 epidemic

Author

Listed:
  • Hakon Jonsson

    (deCODE genetics/Amgen, Inc.)

  • Olafur T. Magnusson

    (deCODE genetics/Amgen, Inc.)

  • Pall Melsted

    (deCODE genetics/Amgen, Inc.
    University of Iceland)

  • Jonas Berglund

    (deCODE genetics/Amgen, Inc.)

  • Arna B. Agustsdottir

    (deCODE genetics/Amgen, Inc.)

  • Berglind Eiríksdottir

    (deCODE genetics/Amgen, Inc.)

  • Run Fridriksdottir

    (deCODE genetics/Amgen, Inc.)

  • Elisabet Eir Garðarsdottir

    (deCODE genetics/Amgen, Inc.)

  • Gudmundur Georgsson

    (deCODE genetics/Amgen, Inc.)

  • Olafia S. Gretarsdottir

    (Landspitali University Hospital)

  • Kjartan R. Guðmundsson

    (deCODE genetics/Amgen, Inc.)

  • Thora Rosa Gunnarsdottir

    (Landspitali University Hospital)

  • Hannes Eggertsson

    (deCODE genetics/Amgen, Inc.)

  • Arnaldur Gylfason

    (deCODE genetics/Amgen, Inc.)

  • Hilma Holm

    (deCODE genetics/Amgen, Inc.)

  • Brynjar O. Jensson

    (deCODE genetics/Amgen, Inc.)

  • Aslaug Jonasdottir

    (deCODE genetics/Amgen, Inc.)

  • Frosti Jonsson

    (deCODE genetics/Amgen, Inc.)

  • Kamilla S. Josefsdottir

    (Directorate of health)

  • Marianna Thordardottir

    (Directorate of health)

  • Karl G. Kristinsson

    (Landspitali University Hospital)

  • Þórður Kristjánsson

    (deCODE genetics/Amgen, Inc.)

  • Droplaug N. Magnusdottir

    (deCODE genetics/Amgen, Inc.)

  • Louise le Roux

    (deCODE genetics/Amgen, Inc.)

  • Jona Saemundsdottir

    (deCODE genetics/Amgen, Inc.)

  • Asgeir Sigurdsson

    (deCODE genetics/Amgen, Inc.)

  • Gudrun Sigmundsdottir

    (Directorate of health)

  • Gardar Sveinbjornsson

    (deCODE genetics/Amgen, Inc.)

  • Solvi Rognvaldsson

    (deCODE genetics/Amgen, Inc.)

  • Ogmundur Eiriksson

    (deCODE genetics/Amgen, Inc.)

  • Magnus Karl Magnusson

    (deCODE genetics/Amgen, Inc.)

  • Kristin Eva Sveinsdottir

    (deCODE genetics/Amgen, Inc.)

  • Maney Sveinsdottir

    (Landspitali University Hospital)

  • Emil Aron Thorarensen

    (deCODE genetics/Amgen, Inc.)

  • Bjarni Thorbjornsson

    (deCODE genetics/Amgen, Inc.)

  • Arthur Löve

    (Landspitali University Hospital)

  • Gudmundur L. Norddahl

    (deCODE genetics/Amgen, Inc.)

  • Ingileif Jonsdottir

    (deCODE genetics/Amgen, Inc.
    Landspitali University Hospital)

  • Patrick Sulem

    (deCODE genetics/Amgen, Inc.)

  • Gisli Masson

    (deCODE genetics/Amgen, Inc.)

  • Alma Moller

    (Directorate of health)

  • Thorolfur Gudnason

    (Directorate of health)

  • Mar Kristjansson

    (Landspitali University Hospital)

  • Agnar Helgason

    (deCODE genetics/Amgen, Inc.
    University of Iceland)

  • Daniel F. Gudbjartsson

    (deCODE genetics/Amgen, Inc.
    University of Iceland)

  • Unnur Thorsteinsdottir

    (deCODE genetics/Amgen, Inc.
    Landspitali University Hospital)

  • Kari Stefansson

    (deCODE genetics/Amgen, Inc.
    Landspitali University Hospital)

Abstract

A pressing concern in the SARS-CoV-2 epidemic and other viral outbreaks, is the extent to which the containment measures are halting the viral spread. A straightforward way to assess this is to tally the active cases and the recovered ones throughout the epidemic. Here, we show how epidemic control can be assessed with molecular information during a well characterized epidemic in Iceland. We demonstrate how the viral concentration decreased in those newly diagnosed as the epidemic transitioned from exponential growth phase to containment phase. The viral concentration in the cases identified in population screening decreased faster than in those symptomatic and considered at high risk and that were targeted by the healthcare system. The viral concentration persists in recovering individuals as we found that half of the cases are still positive after two weeks. We demonstrate that accumulation of mutations in SARS-CoV-2 genome can be exploited to track the rate of new viral generations throughout the different phases of the epidemic, where the accumulation of mutations decreases as the transmission rate decreases in the containment phase. Overall, the molecular signatures of SARS-CoV-2 infections contain valuable epidemiological information that can be used to assess the effectiveness of containment measures.

Suggested Citation

  • Hakon Jonsson & Olafur T. Magnusson & Pall Melsted & Jonas Berglund & Arna B. Agustsdottir & Berglind Eiríksdottir & Run Fridriksdottir & Elisabet Eir Garðarsdottir & Gudmundur Georgsson & Olafia S. G, 2021. "Molecular benchmarks of a SARS-CoV-2 epidemic," Nature Communications, Nature, vol. 12(1), pages 1-8, December.
  • Handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-23883-6
    DOI: 10.1038/s41467-021-23883-6
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-021-23883-6
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-021-23883-6?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-23883-6. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.